TABLE 3.

MVA results for estrogen receptor positive cohort.

	Multi variable analysis
NCDB variable	Hazard Ratio (95% CI)	p Value
HER2‐low	0.92 (0.87–0.96)	0.001
Age at diagnosis [years]	1.02 (1.02–1.02)	<0.001
Identify as Hispanic	0.90 (0.83–0.97)	0.005
Identify race as Black	0.81 (0.73–0.91)	<0.001
N Stage 1	1.22 (1.15–1.29)	<0.001
N Stage 2	1.13 (1.03–1.22)	0.007
N Stage 3	1.23 (1.13–1.33)	<0.001
T Stage 0	_	_
T Stage 1	1.65 (1.36–2.00)	<0.001
T Stage 2	1.87 (1.54–2.26)	<0.001
T Stage 3	2.10 (1.73–2.55)	<0.001
T Stage 4	2.15 (1.78–2.59)	<0.001
Charlson‐Deyo score of 0	_	_
Charlson‐Deyo score of 1	1.28 (1.21–1.36)	<0.001
Charlson‐Deyo score of 2	1.50 (1.35–1.67)	<0.001
Charlson‐Deyo score of 3	1.66 (1.42–1.95)	<0.001
Systemic Therapy	0.97 (0.91–1.05)	0.45
Year of Diagnosis 2008–2011 vs 2012–2015	1.06 (1.01–1.12)	0.025
No Insurance	_	_
Private insurance	0.72 (0.65–0.79)	<0.001
Medicaid	0.84 (0.76–0.92)	<0.001
Medicare	0.75 (0.62–0.92)	0.005
Distance of patient residence—reporting Hospital [miles]	1.00 (1.00–1.00)	0.866
Urban/suburban area	0.99 (0.92–1.06)	0.757
Rural area	1.05 (0.90–1.24)	0.524